Robert Ghenchev
Direktor/Vorstandsmitglied bei OXFORD BIOMEDICA PLC
Profil
Robert Ghenchev is currently a Non-Executive Director at Oxford Biomedica Plc, a Director at Mission Bio, Inc., a Director at Exscientia AI Ltd., a Director at Exscientia Plc, a Director at Mightyowl, Inc., a Director at Quanta Dialysis Technologies, Inc., a Partner & Head of Novo Growth at Novo Principal Investments, a Senior Partner & Head of Novo Growth at Novo Holdings A, and a Managing Partner at Novo Holdings Equity Us, Inc. Previously, he worked as a Senior Vice President at Moelis & Co. (UK) LLP from 2010 to 2018.
He holds a graduate degree from the University of Oxford and an undergraduate degree from McGill University.
Aktive Positionen von Robert Ghenchev
| Unternehmen | Position | Beginn |
|---|---|---|
| OXFORD BIOMEDICA PLC | Direktor/Vorstandsmitglied | 24.06.2019 |
| EXSCIENTIA PLC | Direktor/Vorstandsmitglied | 01.05.2020 |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Direktor/Vorstandsmitglied | 01.01.2018 |
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01.01.2018 |
Tempus Labs, Inc.
 Tempus Labs, Inc. Information Technology ServicesTechnology Services Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL. | Direktor/Vorstandsmitglied | 01.05.2019 |
Exscientia AI Ltd.
 Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Direktor/Vorstandsmitglied | 01.05.2020 |
Mission Bio, Inc.
 Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | - |
| Mightyowl, Inc. | Direktor/Vorstandsmitglied | - |
| Novo Holdings Equity Us, Inc. | Corporate Officer/Principal | - |
| ░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ehemalige bekannte Positionen von Robert Ghenchev
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░ ░░░░░ ░░░ ░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Robert Ghenchev
| University of Oxford | Graduate Degree |
| McGill University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| OXFORD BIOMEDICA PLC | Health Technology |
| EXSCIENTIA PLC | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Moelis & Co. (UK) LLP
 Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010. | Finance |
Tempus Labs, Inc.
Tempus Labs, Inc. Information Technology ServicesTechnology Services Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL. | Technology Services |
Mission Bio, Inc.
Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Commercial Services |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Finance |
| Mightyowl, Inc. | |
| Novo Holdings Equity Us, Inc. | |
| Quanta Dialysis Technologies, Inc. |
